Clinical Trial DesignThe FDA waives bot monotherapy requirement for Phase 3 design, supporting a simplified trial structure.
Equity InvestmentZydus will make a $16M strategic equity investment in Agenus, providing the essential capital needed to accelerate a Phase 3 trial of botensilimab and balstilimab in MSS-CRC.
Strategic CollaborationThe strategic collaboration with Zydus is valued at up to $141M and aims to accelerate the clinical development of botensilimab and balstilimab while securing scaled manufacturing.